Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

Phase 2
Recruiting
Conditions
AML, Adult
Interventions
Drug: azacitidine
Drug: Venetoclax
Drug: Cobicistat
First Posted Date
2023-08-28
Last Posted Date
2024-01-18
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Target Recruit Count
142
Registration Number
NCT06014489
Locations
🇳🇱

NL-Leeuwarden-MCL, Leeuwarden, Netherlands

🇳🇱

NL-Enschede-MST, Enschede, Netherlands

🇳🇱

NL-Eindhoven-MAXIMAMC, Eindhoven, Netherlands

and more 15 locations

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

First Posted Date
2023-08-18
Last Posted Date
2024-06-04
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
36
Registration Number
NCT05996406
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, China

Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

Early Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Drug: Venetoclax
First Posted Date
2023-08-04
Last Posted Date
2024-03-28
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
3
Registration Number
NCT05976217
Locations
🇺🇸

UAB, Birmingham, Alabama, United States

🇺🇸

TKC, Birmingham, Alabama, United States

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

First Posted Date
2023-07-27
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
320
Registration Number
NCT05963074
Locations
🇺🇸

Cancer and Blood Specialty Clinic, Los Alamitos, California, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

🇮🇹

ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

and more 68 locations

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

First Posted Date
2023-07-21
Last Posted Date
2024-12-20
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
70
Registration Number
NCT05955261
Locations
🇺🇸

Rady Children's Hospital-San Diego, San Diego, California, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Cook Children's Medical Center, Fort Worth, Texas, United States

and more 2 locations

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

Phase 2
Active, not recruiting
Conditions
Mantle Cell Lymphoma (MCL)
Interventions
Drug: Acalabrutinib
Drug: Venetoclax
Drug: Rituximab
First Posted Date
2023-07-19
Last Posted Date
2024-11-22
Lead Sponsor
AstraZeneca
Target Recruit Count
108
Registration Number
NCT05951959
Locations
🇬🇧

Research Site, Plymouth, United Kingdom

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

First Posted Date
2023-07-17
Last Posted Date
2024-12-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
720
Registration Number
NCT05947851
Locations
🇹🇷

Mega Medipol-Hematology ( Site 4904), İstanbul, Turkey

🇺🇸

Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States

🇺🇸

MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States

and more 46 locations

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2023-06-20
Last Posted Date
2024-11-18
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
100
Registration Number
NCT05910801
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Venetoclax
First Posted Date
2023-06-18
Last Posted Date
2023-12-01
Lead Sponsor
AbbVie
Target Recruit Count
15
Registration Number
NCT05909553
Locations
🇺🇸

Acpru /Id# 255783, Grayslake, Illinois, United States

Venetoclax Combined With Azactidine in the Treatment of ALAL

First Posted Date
2023-06-13
Last Posted Date
2024-07-23
Lead Sponsor
Sheng-Li Xue, MD
Target Recruit Count
22
Registration Number
NCT05901974
Locations
🇨🇳

The First Affliated Hospital of Soochow University, Suzhou, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy